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BACKGROUND: Despite neoadjuvant/adjuvant chemotherapy, women with resectable stage II/III breast cancer (BC) have high risk
of recurrent disease. Recent data suggest that zoledronic acid (ZOL) therapy concurrent with adjuvant treatments may improve
cancer-related outcomes in patients with BC.
METHODS: Disease-free survival (DFS; secondary end point) and overall survival (OS; tertiary end point) were evaluated in 119 women
with stage II/III BC randomised to intravenous ZOL 4mg every 3 weeks for 1 year or no ZOL (control) starting with the first
chemotherapy cycle.
RESULTS: At 61.9 months’ median follow-up, there was no significant difference in recurrence or survival between study arms.
However, time to recurrence or death (DFS) was significantly different between subgroups defined by oestrogen receptor (ER)
status (interaction P¼0.010 for DFS and 0.025 for OS). Hazard ratios (HRs) for disease recurrence and death were significantly less
among patients with ER-negative (ER
 ) tumours who received ZOL vs no ZOL (DFS: HR¼0.361, 95% confidence interval (CI)
0.148, 0.880; OS: HR¼0.375, 95% CI 0.143, 0.985).
CONCLUSION: ZOL administered with chemotherapy may improve DFS and OS in a subset of BC patients with ER
  tumours. This
study was not powered to compare subgroups of patients; thus, these findings should be considered hypothesis generating.
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Breast cancer (BC) is the most commonly diagnosed malignancy
and the leading cause of cancer-related mortality among women
worldwide (Ferlay et al, 2010). Despite the use of neoadjuvant and
adjuvant therapies in patients with localised BC, recent trials
report B8% incidence of disease recurrence overall within the first
few years after treatment, with even higher recurrence rates for
patients with certain BC subtypes (Gnant et al, 2009; Eidtmann
et al, 2010). The development of recurrent disease is thought to be
the result of persistent micro-metastatic disease that is chemother-
apy resistant (Pantel et al, 2009). The presence and persistence of
disseminated tumour cells (DTCs), also known as bone marrow
micro-metastases, have been associated with poor outcomes and
recurrent disease in patients with early-stage BC, regardless of
hormone receptor status and other established prognostic features
such as nodal status (Braun et al, 2005). We and others have
reported that the bone-targeted bisphosphonate, zoledronic acid
(ZOL), which is currently used to treat osteoporosis and to reduce
the risk of skeletal morbidity in patients with bone metastases, can
also reduce the persistence of DTCs in the bone marrow of women
with early BC (Lin et al, 2008; Solomayer et al, 2009; Aft et al, 2010;
Rack et al, 2010).
Zoledronic acid has been reported to decrease tumour burden in
the breast when administered with neoadjuvant chemotherapy
(Coleman et al, 2010). In addition, we observed that subsets of
patients with triple-negative BC were more likely to have a
pathologic complete response (pCR) to neoadjuvant chemotherapy
if they received concurrent ZOL, suggesting that bisphosphonates
may provide potential anti-cancer benefits in addition to their
established bone-protective activities (Neville-Webbe et al, 2010).
Numerous studies have evaluated the impact of bisphosphonates
on disease-free survival (DFS) and overall survival (OS) in
localised BC. Although the results have been mixed, consensus is
emerging that certain subsets of patients with early-stage BC may
benefit from bisphosphonate therapy. Zoledronic acid adminis-
tration increased DFS in premenopausal women with oestrogen
receptor-positive (ER
þ) BC who were treated with ovarian
suppression and endocrine-targeted therapies (Gnant et al,
2011a). Likewise, ZOL increased DFS in postmenopausal women
with ER
þ tumours who received endocrine-targeted therapies
(Eidtmann et al, 2010; Coleman et al, 2011). The mechanisms of
the anti-cancer effects of bisphosphonates are under intense
investigation.
In this study, we report the effect of ZOL administered every 3
weeks for 1 year, beginning at the start of neoadjuvant
chemotherapy, on DFS and OS outcomes in a phase II trial of
120 women with stage II/III BC, which included pre- and
postmenopausal women and patients with ER
þ and ER-negative
(ER
 ) tumours (Aft et al, 2010).
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Patients
Eligible patients had clinical stage II/III (XT2 and/or XN1) newly
diagnosed BC with inclusion of all tumour biomarker subtypes,
Eastern Cooperative Oncology Group performance status score of
0 or 1, and normal cardiac, renal and liver function. Menopausal
status was defined as 1 year with no menstrual activity, previous
bilateral oophorectomy, or age 456 years. Inclusion criteria for
this study were as previously described (Aft et al, 2010).
Study design and treatment
This single-centre, open-label, phase II trial evaluated the efficacy
and safety of adding ZOL to standard therapy in women with stage
II/III BC. This study is registered with ClinicalTrials.gov,
NCT00242203. Eligible women were randomly assigned to receive
either 4mg intravenous ZOL every 3 weeks for 1 year (total 17
doses) commencing with the first dose of chemotherapy, or no
ZOL (chemotherapy alone; Figure 1). The randomisation process
was as previously described (Aft et al, 2010).
The primary end point was the number of patients with
detectable DTCs in bone marrow, measured at baseline, 3 months
(after four cycles of chemotherapy), and 12 months. These results
have been reported earlier (Aft et al, 2010). Respective secondary
and tertiary end points were DFS, defined as the time interval
between surgery (the time point of all residual disease removal)
and first detectable disease recurrence or death, and OS, defined
as the time from diagnosis to death from any cause or to last
follow-up.
The approved dosing schedule of ZOL (4mg via 15-min
intravenous infusion every 3 weeks) for bone metastasis was used
(Hillner et al, 2003). All women received four cycles of intravenous
neoadjuvant epirubicin (75mgm
 2) plus docetaxel (75mgm
 2)
every 3 weeks, with granulocyte-stimulating factor support and
oral dexamethasone premedication (20mg), followed by surgery
and two cycles of adjuvant epirubicin plus docetaxel administered
every 3 weeks. Adjuvant radiation, endocrine, and trastuzumab
therapies were administered when indicated. The recommended
follow-up was every 3 months for years 1 and 2 after randomisa-
tion, then every 6 months for years 3–5 after randomisation. It was
recommended that all radiological exams (i.e., mammogram,
computed tomography, bone or positron emission tomography)
be performed annually.
All patients were encouraged to take 1000mg calcium with 800IU
vitamin D daily. Adverse events were assessed at each follow-up.
Patients were removed from the study for safety reasons,
progression during chemotherapy or recurrent disease develop-
ment. The Internal Review Board of Washington University
approved the study, and patients provided written consent.
Study assessments
Immunostaining for ER, progesterone receptor (PgR), and human
epidermal growth factor receptor-2 (HER2) was performed at
Washington University. ER and PgR were considered positive if
there was any detectable staining by immunohistochemistry
(Ventana, Inc., Tucson, AZ, USA). HER2 was considered positive
if HercepTest (Dako North America, Inc., Carpinteria, CA, USA)
was 3
þ or if the fluorescence in situ hybridisation (FISH) score
was 42.0. The FISH analysis was done for all specimens scored as
2
þ by HercepTest.
Pre-treatment tumour size was defined as the largest tumour
dimension documented by mammogram, breast ultrasound, or
magnetic resonance imaging. Pre-treatment lymph-node status
was defined as any abnormal lymph nodes on computed
tomography or ultrasound imaging, or on clinical exam, or by
the presence of metastatic disease from fine-needle aspiration or
sentinel lymph-node biopsy. Pathologic complete response was
defined as no residual invasive tumour in the breast specimen at
the time of surgery.
Statistical analysis
Kaplan–Meier estimates were generated for DFS and OS in each
treatment arm, and patient subsets were defined by ER and HER2
status. Hazard ratios (HRs) and 95% confidence intervals (CIs)
were calculated using Cox proportional hazards models.
A propensity score, adjusting for differences in age, race,
menopausal status, ER, PgR, and HER2, was found to be a
significant predictor of DFS and OS; thus, all reported analyses
were adjusted using the propensity score. P-values o0.05 were
considered significant.
RESULTS
Patients
Of the 120 eligible women enrolled in this study, 119 were
evaluated, and of those patients B55% had ER
þ tumours, 20%
had HER2
þ tumours, and 33% had ER
 /HER2
  tumours
(Table 1; Aft et al, 2010). One patient withdrew consent before
receiving treatment, one patient did not have tumour biomarkers,
and two patients did not undergo surgery for their cancer. Thirty-
seven patients developed recurrent disease, of whom 27 died and
10 were alive with disease at last follow-up. There were 18 deaths
among the 52 ER
  patients and 9 deaths among the 66 ER
þ
patients. The remaining 82 patients were alive without disease at
last follow-up. No deaths were identified within this cohort as
having a cause unrelated to BC.
Efficacy
After a median follow-up of 61.9 months, DFS (P¼0.92) and
OS (P¼0.92) were similar in the ZOL and no-ZOL arms for the
overall study population (Figure 2). ER status is an independent
predictor of OS (Berry et al, 2006) and, as expected in our
study, times to recurrence and death were significantly different
between patient subgroups defined by ER status in the no-ZOL
arm (interaction P¼0.010 for DFS and 0.025 for OS; Table 2).
However, in the ZOL treatment arm we failed to find a differences
among the ER
þ and ER
  patients. The hazards of disease
recurrence and of death were significantly less among patients
with ER
  tumours who received ZOL vs those who did not
(DFS: HR¼0.361; 95% CI 0.148, 0.880; OS: HR¼0.375; 95% CI
0.143, 0.985). There was no evidence that ZOL treatment altered
DFS or OS vs no ZOL in patients with ER
þ tumours (Table 3).
In Kaplan–Meier analyses, there were significant differences in DFS
(P¼0.0007) and OS (P¼0.0018) based on treatment arms (Figure 3).
Epirubicin/docetaxel ×4
Patients with
clinical
stage II/III
breast cancer
Epirubicin/docetaxel ×2
+/– standard therapy
Epirubicin/docetaxel ×2
+ ZOL (4 mg IV) q 3 weeks
+/– standard therapy
Follow-up for
DFS and OS
DTC assessment Baseline DTC assessment
Epirubicin/docetaxel ×4
+ ZOL (4 mg IV) q 3 weeks
S
u
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Figure 1 Study design. Abbreviations: DFS¼disease-free survival;
DTC¼disseminated tumour cells; IV¼intravenous; OS¼overall survival;
ZOL¼zoledronic acid (4mg every 3 weeks).
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þ status has significant effects on DFS and OS,
especially with the recent adoption of HER2-targeted therapy, and
to analyse more uniform subsets of BC patients, we analysed the
effects of ER status on DFS and OS in the subset of patients with
HER2
  tumours (n¼95). In the subset of HER2
  tumours, the
effect of ZOL on OS and DFS was not shown to be significantly
different in ER
þ and ER
  patients (DFS interaction P¼0.052 and
OS interaction P¼0.064; Table 2). However, among patients with
ER
 /HER2
  tumours, only 58% were alive at last follow-up in the
no-ZOL arm compared with 81% in the ZOL arm. The
corresponding DFS rates were 47% (no ZOL) and 71% (ZOL).
Safety
As previously reported, ZOL was generally well tolerated; toxicities
were similar in the two treatment groups, with no observed cases
of nephrotoxicity resulting in dose modifications. One of the 60
patients (1.7%) developed osteonecrosis of the jaw after receiving
11 infusions of ZOL (Aft et al, 2010).
DISCUSSION
With a median follow-up of 62 months, the addition of
neoadjuvant ZOL to standard therapy did not significantly change
median DFS or OS in women with stage II/III BC treated in
this study. This is consistent with our earlier report in which we
Table 1 Patient demographics and baseline disease characteristics
Characteristic No ZOL (n¼59) ZOL (n¼60)
Mean age, years (range) 49.1 (32–69) 50 (30–68)
Race, n (%)
Caucasian 45 (76.3) 39 (65)
African American 11 (18.6) 20 (33)
Menopausal status, n (%)
Premenopausal 33 (55.9) 31 (51.7)
Postmenopausal 26 (44.1) 29 (48.3)
Pathology, n (%)
Ductal carcinoma 49 (83.1) 47 (78.3)
Lobular carcinoma 7 (11.8) 7 (11.7)
Other 3 (5.1) 6 (10)
Mean tumour size, cm (s.d.) 3.56 (2.41) 3.81 (2.03)
Lymph-node positive, n (%) 33 (55.9) 38 (63.3)
Grade, n (%)
I 2 (3.4) 7 (11.7)
II 28 (47.5) 20 (33.3)
III 29 (49.2) 33 (55)
Receptor status, n (%)
ER
þ/HER2
þ 5 (8.5) 6 (10)
ER
þ/HER2
  29 (49.2) 26 (43.3)
ER
 /HER2
þ 5 (8.5) 7 (11.7)
ER
 /HER2
  19 (32.2) 21 (35)
Unknown 1 (1.7) —
Abbreviations: ER¼oestrogen receptor; HER2¼human epidermal growth factor
receptor-2; s.d.¼standard deviation; ZOL¼zoledronic acid. Some of these patient
data were previously published (Aft et al, 2010).
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Figure 2 Disease-free survival (A) and overall survival (B) were similar
between the ZOL and no-ZOL arms for the overall trial population.
Abbreviations: DFS¼disease-free survival; OS¼overall survival; ZOL¼
zoledronic acid (4mg every 3 weeks); J¼censored.
Table 2 Proportional hazards by tumour subtype and treatment arm
adjusted for propensity score
P-value
Parameter
Overall
DFS
(N¼119)
Overall
OS
(N¼119)
HER2
 
DFS
(N¼95)
HER2
 
OS
(N¼95)
Treatment, ZOL vs no ZOL 0.14 0.17 0.36 0.32
Propensity score 0.038 0.02 0.026 0.023
ER status, ER
þ vs ER
  0.0012 0.0042 0.025 0.022
Treatment by ER status,
interaction
0.01 0.025 0.064 0.052
Abbreviations: DFS¼disease-free survival; ER¼oestrogen receptor; HER2¼human
epidermal growth factor receptor-2; OS¼overall survival; ZOL¼zoledronic acid.
Table 3 Risk of recurrence or death by tumour subtype and treatment arm
Hazard ratio (95% confidence interval)
Parameter
Overall
DFS
Overall
OS
HER2
 
DFS
HER2
 
OS
Treatment in ER
  0.361
(0.148, 0.880)
0.375
(0.143, 0.985)
0.374
(0.125, 1.12)
0.306
(0.091, 1.04)
Treatment in ER
þ 2.43
(0.748, 7.90)
3.07
(0.626, 15.1)
1.78
(0.512, 6.21)
2.32
(0.440, 12.2)
ER
  vs ER
þ in ZOL 0.958
(0.377, 2.43)
1.12
(0.391, 3.18)
0.832
(0.262, 2.64)
0.835
(0.222, 3.14)
ER
  vs ER
þ in no ZOL 6.45
(2.08, 20.0)
9.15
(2.01, 41.6)
3.96
(1.19, 13.2)
6.32
(1.31, 30.4)
Propensity score,
per 0.01 increase
1.03
(1.002, 1.06)
1.04
(1.01, 1.08)
1.05
(1.01, 1.09)
1.06
(1.01, 1.11)
Abbreviations: DFS¼disease-free survival; ER¼oestrogen receptor; HER2¼human
epidermal growth factor receptor-2; OS¼overall survival; ZOL¼zoledronic acid.
Treatment is ZOL vs no ZOL.
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Figure 3 Kaplan–Meier estimates of (A) disease-free survival and (B)
overall survival in all patients according to the ER status of their tumours.
Abbreviations: DFS¼disease-free survival; ER¼oestrogen receptor;
ZOL¼zoledronic acid (4mg every 3 weeks); J¼censored.
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sdid not observe significant differences in the 1- and 2-year disease
recurrence and survival rates (Aft et al, 2010). Analysis of survival
rates stratified according to BC subtype revealed significant
improvements in DFS and OS in women with ER
  tumours
randomised to receive ZOL. Our data are consistent with a recent
report demonstrating a survival benefit of bisphosphonates in
ER
  patients with metastatic disease (Park et al, 2009). In most
adjuvant trials with bisphosphonates in non-metastatic BC, the
predominant tumour type is ER
þ. Our trial was intentionally
geared to patients at high risk of metastasis; 440% of patients
treated in our trial had ER
  tumours and were premenopausal at
diagnosis.
Three recently reported large phase III trials, which included
women with all tumour subtypes, did not demonstrate an
overall DFS or OS benefit from bisphosphonate treatment in
women receiving adjuvant chemotherapy. These trials were the
National Surgical Adjuvant Breast and Bowel Project (NSABP)
B-34 trial, which compared clodronate vs placebo in women with
early BC treated with adjuvant chemotherapy or endocrine
therapy, the German Adjuvant Intergroup Node-positive (GAIN)
study, which compared ibandronate vs placebo in women receiving
adjuvant chemotherapy, and the Adjuvant Zoledronic Acid to
Reduce Recurrence (AZURE) study, which compared ZOL vs
placebo in women receiving adjuvant chemotherapy or endocrine
therapy (Coleman et al, 2011; Mobus et al, 2011; Paterson et al,
2011). In contrast, other trials evaluating the addition of ZOL (4mg
every 6 months) to endocrine therapy demonstrated significant
improvement in DFS compared with adjuvant endocrine therapy
alone in premenopausal women with ovarian suppression in phase
III trials (N¼1803; DFS HR¼0.64; P¼0.01; Gnant et al, 2009) and
postmenopausal (N¼1065; DFS HR¼0.59; P¼0.03; Eidtmann
et al, 2010) women with stage I to III BC. However, clinical data
indicate that ER status may be a variable for clinical benefit from
bisphosphonates in this setting.
In a subset analysis of the AZURE trial in patients who were
unequivocally postmenopausal at the time of starting the trial, ZOL
provided a benefit for DFS to those patients with ER
þ tumours
(Coleman et al, 2011). We await OS data from the planned
subgroup analysis by tumour subtype of the NSABP B-34 and
GAIN trials. Meanwhile, in the ABCSG-12 trial, those women who
derived the greatest benefit from the addition of ZOL were 440
years of age at study entry (Gnant et al, 2011b). These studies
suggest that women with ER
þ tumours and low oestrogen levels
(postmenopausal, or premenopausal women with ovarian suppres-
sion) experience a survival benefit when ZOL is administered in
the adjuvant setting. In this study, we did not observe any DFS
benefit with the addition of ZOL to standard therapy in the subset
of patients with ER
þ tumours. The lack of DFS benefit in ER
þ
patients may be related to the small number of events in this
subgroup with a more favourable prognosis compared with ER
 
patients. The ER
þ patients in this study were relatively young
(median age, 47 years) and may have benefitted from upfront
neoadjuvant chemotherapy because of their high-risk status
(tumour size and other risk factors). As 60% of the patients with
ER
þ tumours in this trial were premenopausal at diagnosis,
in contrast to the AZURE population, and were not given
ovarian suppression, in contrast to the Austrian Breast and
Colorectal Cancer Study Group trial 12 (ABCSG-12) population,
it is difficult to extrapolate the results of our trial to others
(Gnant et al, 2009).
Many bisphosphonate trials have focused on patients with ER
þ
disease or have not included a large population of patients with
ER
  disease. Few studies have examined the effects of bispho-
sphonates on ER
  BCs. In a retrospective study, Park et al (2009)
found significantly prolonged survival in ER
  stage IV BC patients
who received bisphosphonate treatment. In our trial, we found a
significant decreased risk of recurrent disease development and
death in patients with ER
  disease who received ZOL (HR¼0.361
and 0.375, respectively). We observed 21 recurrences among the 50
ER
  patients. This population was composed of predominantly
premenopausal (55%) and African American (45%) women. Thus,
in contrast to ER
þ tumours, the effect does not seem to be
dependent on a low oestrogen environment and may be the result
of a more direct anti-tumour effect of ZOL on ER
  tumour cells.
In the primary report of this study, it was shown that adding
ZOL to neoadjuvant chemotherapy was associated with increased
rates of pCR vs no ZOL, although this difference was not
significant (Aft et al, 2010). For Luminal B, HER2
þ, and ER
 /
HER2
  BC subtypes, response in the breast correlates with OS,
which is thought to reflect the response of systemic
micro-metastatic disease (Von Minckwitz et al, 2011). Thus,
patients who achieve a pCR in the breast with chemotherapy have
a better prognosis than patients who have residual breast
disease (Chavez-MacGregor and Gonzalez-Angulo, 2010).
Pathologic complete response in the breast has been used as a
surrogate for response to therapy. As previously reported, in
our patient population the between-group differences in the
pCR rate were most pronounced in the triple-negative subset
(ER
 /PgR
 /HER2
 ; ZOL group¼28%; no-ZOL group¼10%),
although, as with the overall population, this difference
was not statistically significant (Aft et al, 2010). These data are
consistent with previous clinical data from the neoadjuvant
therapy subset (n¼205) of the ongoing AZURE trial, wherein
the addition of ZOL (4mg every 3 to 4 weeks) to 6 cycles of
neoadjuvant chemotherapy improved pCR rates approximately
two-fold in a multivariate analysis of the entire neoadjuvant cohort
and significantly reduced the residual invasive tumour size at
surgery (relative decrease of 43%; P¼0.006) vs chemotherapy
alone (Coleman et al, 2010).
As previously reported, among patients without detectable DTCs
at baseline, a larger proportion of ZOL-treated patients (87%)
remained DTC
  at 3 months compared with patients receiving
chemotherapy alone (60%; P¼0.03; Aft et al, 2010). Similarly,
among patients who were DTC
þ at baseline, a larger proportion of
patients transitioned to DTC
  status in the ZOL group (48%)
compared with chemotherapy alone (43%; P¼0.05 vs no ZOL; Aft
et al, 2010). Emerging data suggest that there is a complex
interaction between the tumour and bone marrow (McAllister and
Weinberg, 2010). Primary tumours release cytokines that are
thought to prime the bone marrow for receipt of micro-metastasis
disease, interrupt the delicate balance between bone formation and
destruction with the release of growth factors, and recruit bone
marrow-derived cells to enhance tumour growth and invasion.
Similarly, bone marrow-derived myeloid cells can promote tumour
growth at primary and distant sites (Weilbaecher et al, 2011). It is
possible that drugs such as ZOL affect this interaction with the
observed results of tumour growth inhibition and reduction of
DTCs and metastases formation (Aft, 2011).
Although multiple statistical models used in the current study
show a trend of increased clinical benefit in ER
  patients treated
with ZOL, our findings are limited in that time to relapse (i.e., DFS)
and OS were secondary and tertiary end points, respectively, and
the study was not designed or powered to compare subgroups of
patients. Thus, our findings should be regarded as hypothesis
generating, and interpretation should be regarded with appro-
priate caution.
In summary, in this study, adding ZOL (4mg every 3 weeks) to
neoadjuvant chemotherapy reduced DTC persistence (Aft et al,
2010), improved pCR rates in specific patient subsets (Aft et al,
2010), and improved DFS and OS vs chemotherapy alone in the
patient subset with ER
  tumours. These observations in the ER
 
subset suggest that neoadjuvant or adjuvant ZOL may be a
beneficial addition to current treatment paradigms in patients with
ER
  tumours, and may warrant further investigation in larger
clinical trials in this high-risk patient population with few targeted
therapy options.
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